

Centers for Disease Control and Prevention
National Center for Immunization and Respiratory Diseases



Adult Respiratory Syncytial Virus (RSV) Session

Camille Kotton, MD

Chair, Adult RSV Work Group

Advisory Committee on Immunization Practices (ACIP)

October 25, 2023

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

In June 2023, CDC's Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults ages 60 years and older may receive a single dose of RSV vaccine using shared clinical decision making.

- **RSVPreF3** (Arexvy, GSK) is a 1-dose adjuvanted (ASo1_E) recombinant prefusion F protein (preF) vaccine.
- **RSVpreF** (Abrysvo, Pfizer) is a 1-dose recombinant preF vaccine.

Issues under discussion since the June meeting

- The Work Group reviewed CDC vaccine safety surveillance plans for RSV vaccination in adults ≥ 60 years.
- GSK shared with the Work Group results of an immuno-bridging study showing non-inferior humoral immune responses to RSV vaccination in immunocompetent adults 50–59, compared with immunocompetent adults ≥ 60 (in whom efficacy was demonstrated).
- The Work Group discussed the potential role of RSV vaccination in adults younger than 60 years, including subpopulations that would benefit most from vaccination and equity implications.

Issues under discussion since the June meeting

- The Work Group reviewed CDC vaccine safety surveillance plans for RSV vaccination in adults ≥ 60 years.
 - V-safe (<https://vsafe.cdc.gov>) has launched for older adult RSV vaccination
 - Today's session will not include RSV vaccine uptake data or safety surveillance data; data are premature this early into the vaccination program
 - Uptake and safety results will be shared at a future ACIP meeting



Agenda: Wednesday October 25, 2023

- RSVPreF3 safety and immunogenicity in adults aged 50–59 years, compared with adults aged ≥ 60 years
- Epidemiology of RSV hospitalization in adults, with a focus on adults aged 50–59 years
- Work Group considerations regarding RSV vaccination in adults aged 50–59 years

Dr. Susan Gerber (GSK)

Dr. Monica Patton (CDC)

Dr. Amadea Britton (CDC)



Adult RSV Work Group Membership

ACIP Voting Members

Camille Kotton (Chair)
Keipp Talbot
Sarah Long

Ex Officio Members


Rachel Zhang (FDA)
Judy Beeler (FDA)
Nicholas Geagan (FDA)
Nadine Peart Akindede (FDA)
Sonnie Kim (NIH/NIAID)
Jeffrey Kelman (CMS)
Michelle Juaneza (HRSA/VICP)
Uzo Chukwuma (IHS)
Valerie Marshal (OIDP)

Consultants

Robert Atmar (Baylor Coll. of Medicine)
Helen Chu (U Washington)
Peter Donofrio (Vanderbilt University)
Marie Griffin (Vanderbilt University)
Cynthia Lucero-Obusan (VHA)
Tracy Ruckwardt (NIH/NIAID)
Jonathan Temte (U Wisconsin)
Rebecca Morgan (Case Western)
Doug Campos-Outcalt (U Arizona)

Liaisons

Kenneth Schmader (AGS)
Vidya Sundareshan (ACP)
Gretchen LaSalle (AAFP)
April Killikelly (NACI/PHAC)
Winnie Su (NACI/PHAC)



Katherine Williams (APTR)
Ruth Lynfield (NFID)
Bindy Crouch (AIM)
Steven Pergam (IDSA)
Elizabeth Skoy (APhA)

CDC Contributors

Amadea Britton (co-lead)

Michael Melgar (co-lead)

Lauren Roper

Fiona Havers

Chris Taylor

Monica Patton

Meredith McMorrow

Diya Surie

Jennifer DeCuir

Mila Prill

Monica Godfrey

Ruth Link-Gelles

Amanda Payne

Danielle Moulia

Megan Wallace

Natalie Thornburg

Melissa Coughlin

Jefferson Jones

Katherine Fleming-Dutra

Ismael Ortega Sanchez

Noelle Molinari

Pragna Patel

Aron Hall

Hannah Rosenblum

Derrell Powers

Raigan Wheeler

Jarrett Gartin

Elizabeth Greene

Manisha Patel

Lisa Grohskopf

Anne Hause

David Shay

Christine Olson

Tom Shimabukuro

Karen Broder

Neil Murthy

Patricia Wodi

Andrew Leidner

Jamison Pike

Sarah Meyer

Nicole Dowling



For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

